A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingA First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

Gene Therapy for Alpha-1 Anti-Trypsin Deficiency

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingGene Therapy for Alpha-1 Anti-Trypsin Deficiency

Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingAdvancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingA first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

Microglia replacement therapy for CSF1R-related Leukoencephalopathy

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingMicroglia replacement therapy for CSF1R-related Leukoencephalopathy

TY1 and Semaglutide to Treat Cardiometabolic HFpEF

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingTY1 and Semaglutide to Treat Cardiometabolic HFpEF

CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingCRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia

Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingNoncoding RNA drug TY2 for arrhythmogenic cardiomyopathy

Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders

• Post author:
• Post published:January 6, 2026
• Post category:

Continue ReadingDevelopment of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders